International comparison of the community prevalence of symptoms of prostatism in four countries.
International comparison of the community prevalence of symptoms of prostatism in four countries.
复制标题
四个国家前列腺症状社区患病率的国际比较。
DOI：
10.1159/000473711
复制
发表时间：
1996
期刊：
影响因子：
23.4
通讯作者：
Boyle,P
中科院分区：
文献类型：
--
作者：
Sagnier,PP;Girman,CJ;Garraway,M;Kumamoto,Y;Lieber,MM;Richard,F;MacFarlane,G;Guess,HA;Jacobsen,SJ;Tsukamoto,T;Boyle,P
我们对4个国家的普罗维登的泌尿系统症状的患病率进行了国际比较，采用基于社区的随机抽样受试者，类似的研究程序，以及基于标准化症状问卷的单一病例定义。在苏格兰，来自福斯谷3个社区的1，994名年龄在40-79岁之间的符合医疗条件的男性同意参加。在法国，对2 011名年龄在50-84岁之间的法国男子进行了一项全国性的横断面调查。在美国，奥姆斯特德县（OC）研究招募了年龄和城市/农村分层的2，115名县居民随机样本，这些居民来自年龄在40-79岁之间的符合医疗条件的男性。在日本，来自渔村的290名年龄在40-79岁之间的男性参与了这项研究。苏格兰、法国、OC和日本的应答率分别为55%、53%、55%和43%。泌尿系统症状评估国际前列腺症状评分（I-PSS），计量学验证后，在英语和跨文化适应的问卷。中度至重度症状（1-PSS > 7）的患病率在法国、苏格兰、OC和日本分别为14、18、38和56%。这种模式在几十年内是一致的，并且在大多数个体泌尿系统症状中发现。日本男性报告I-PSS非常低（0或1）的比例分别比OC、苏格兰和法国低约2、4和8倍。报告的泌尿系统症状患病率的差异可能反映了良性前列腺增生真实患病率的国家间差异。然而，在感知和/或愿意报告泌尿系统症状的跨文化差异可能在观察到的差异中发挥重要作用。将需要进一步的研究来阐明所观察到的差异的根本原因。
We conducted an international comparison of the prevalence of urinary symptoms of prostatism in 4 countries, using a community-based random sampling of subjects, similar study procedures, and a single definition of cases that was based on a standardized symptom questionnaire. In Scotland 1,994 medically eligible men aged 40-79 years agreed to participate from 3 communities of the Forth Valley. In France, a nation-wide survey was conducted cross-sectionally in a representative sample of 2,011 French men aged 50-84 years. In the USA, the Olmsted County (OC) study recruited an age- and urban/rural-stratified random sample of 2,115 county residents drawn from medically eligible men aged 40-79 years. In Japan, 290 men aged 40-79 years from a fishing village participated in the study. Response rates were 55, 53, 55, and 43% in Scotland, France, OC and Japan, respectively. Urinary symptoms were assessed by the International Prostate Symptom Score (I-PSS), after metrologie validation in English and cross-cultural adaptation of the questionnaire. The prevalence of moderate to severe symptoms (1-PSS > 7) were 14, 18, 38, and 56% in France, Scotland,OC and Japan, respectively. This pattern was consistent within decades of age, and was found for most of the individual urinary symptoms. The proportion of men in Japan reporting very low I-PSS (0 or 1) was approximately 2,4 and 8 times less frequent, than in OC, Scotland, and France, respectively. Differences in the prevalence of reported urinary symptoms might reflect between-country differences in the true prevalence of benign prostatic hyperplasia. However, cross-cultural differences in the perception and/or willingness to report urinary symptoms may play an important role in the observed differences. Further study will be required to elucidate the underlying causes of the observed differences.